Theratechnologies (THTX) to Release Quarterly Earnings on Thursday

Theratechnologies (NASDAQ:THTX - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, October 10th. Theratechnologies has set its FY 2024 guidance at EPS.

Theratechnologies (NASDAQ:THTX - Get Free Report) last posted its quarterly earnings data on Wednesday, July 10th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.02) by $0.04. The business had revenue of $22.02 million during the quarter. During the same period in the prior year, the company earned ($0.40) earnings per share. On average, analysts expect Theratechnologies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Theratechnologies Price Performance

Theratechnologies stock traded up $0.02 during mid-day trading on Thursday, reaching $1.21. 6,148 shares of the company were exchanged, compared to its average volume of 44,180. Theratechnologies has a 12 month low of $0.88 and a 12 month high of $2.58. The firm has a market cap of $55.50 million, a PE ratio of -6.35 and a beta of 1.41. The company has a fifty day simple moving average of $1.30 and a 200-day simple moving average of $1.34.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.